Pharma forensics is having a momentand its not about lab coats. Its about reading the fine print.
In drug development, the public story is clinical trials, endpoints, and timelines. The private story is formulation: the how behind the what. And if you …
Designing Around the Moat: How Generic Developers Can Navigate Secondary Formulation Patents
In generic drug development, the hardest part isnt always the active ingredientits the moat built around it.
For years, the industry has focused on primary pat…
Designing Around the Moat: A Generic Developer’s Guide to Secondary Formulation Patents Read Post »
Patent cliff or patent opportunity? Mapping blockbuster expirations for strategic supply-chain readiness
The market loves a clean narrative: patent cliff = chaos. But in pharma, the real story is messierand more profitable for companies that plan early…
AI is getting better at finding whats not thereand thats a problem for anyone relying on keyword searches.
For years, patent teams have treated prior-art hunting like a scavenger hunt with a rulebook: plug in the right terms, scan the results, and move…
Beyond Keywords: How AI and NLP Find Hidden Prior Art in Chemical and Biologic Patents Read Post »
Pharma IP isnt just about having patentsits about surviving them.
If youre developing a drug and your competitors formulation patent is looming, youre not just facing a legal hurdle. Youre facing a strategic design constraint that can determine wheth…
How to Design Around Competitor Formulation Patents: A Strategic Pharma IP Playbook Read Post »
Most people read drug patents like legal documents. Formulation forensics reads them like a crime scene.
If youve ever wondered why two similar formulations can behave so differently in the real worldbioavailability, stability, manufacturability, even …
Formulation Forensics: How to Read Excipient and Process Clues in Drug Patent Claims Read Post »
The biosimilar patent dance isnt a formalityits the first move in a multiâyear chess match.
If youre a biologics innovator or a biosimilar applicant, the stakes are obvious: exclusivity, market timing, and the ability to launch on schedule. Whats l…
Generic winners dont wait for exclusivitythey engineer it.
In the Paragraph IV world, 180-day exclusivity is often described like a prize at the end of a race. But the real story is less about luck and more about execution: timing, litigation strateg…
The Patent Dance Is No Longer a ChoreographyIts a Strategy War. Heres the Playbook.
If youve been anywhere near biologics and biosimilars over the last few years, you already know the script: the patent dance under the BPCIA is supposed to bring clarit…
Big Pharma loves to talk about pipelines. But the real competitive edge is increasingly hiding in the supply chainspecifically in the data that predicts what will be available, when, and at what cost.
Thats the thesis behind a new piece from DrugPatent…
Drug Patent Data: The Supply Chain Forecasting Edge Big Pharma Isn’t Talking About Read Post »
Get new actionable insights and updates from BiotechBlog
